Volume 28, Issue 6 (9-2021)                   RJMS 2021, 28(6): 0-0 | Back to browse issues page

Research code: 000
Ethics code: 00
Clinical trials code: 0

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://rjms.iums.ac.ir/article-1-6592-en.html
Iran university of medical science , Saghafi.mm@iums.ac.ir
Abstract:   (328 Views)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that gradually leads to decline in memory and other intellectual functions, changes in personality and behavioral disturbances. With a rapidly aging population in the developed world dementia caused by Alzheimer’s disease is becoming a growing social and economic problem. In Europe, the estimated number of patients who have dementia is over 6 million and more than half of these patients have Alzheimer’s disease. Despite major progress has been made in our understanding of the underlying pathogenesis, the biological basis of AD is still not fully understood. As failures of compounds targeting amyloid beta in clinical trials are repeatedly reported, the prevailing amyloid cascade hypothesis is being questioned in terms of its causality. Other probable etiologies are also emerging, while new drugs are already urgently needed. Registered drug substances for treatment of Alzheimer’s disease are reviewed. They belong to a group of cholinesterase inhibitors (Donepezil, Rivastigmine, Galanthamine, Tacrine) or antagonists of NMDA receptors (Memantine). Some of most popular dietary supplements, derived from plants or animals are presented as well. In addition, we present the most promising synthetic and biological drug substances in development that undergo phase II or phase III of clinical trials.

Type of Study: review article | Subject: Pharmacology

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb